Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Experimental Pathology|January 13, 2009
Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouseMark J Sinnamon, Kathy J Carter, Barbara Fingleton, et al.
Carcinogenesis|February 9, 2008
A protective role of mast cells in intestinal tumorigenesisMark J Sinnamon, Kathy J Carter, Lauren P Sims, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Essential role for mast cell tryptase in acute experimental colitisMatthew J Hamilton, Mark J Sinnamon, Gregory D Lyng, et al.
Cancer & Metabolism|December 8, 2017
PKM2 is not required for colon cancer initiated by APC lossAllison N Lau, William J Israelsen, Jatin Roper, et al.
Plos One|October 4, 2011
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancerJatin Roper, Michael P Richardson, Wei Vivian Wang, et al.
Disease Models & Mechanisms|April 19, 2014
Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human diseasePeter J Belmont, Eva Budinska, Ping Jiang, et al.
Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancerErin M Coffee, Anthony C Faber, Jatin Roper, et al.
Science Signaling|November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFRPeter J Belmont, Ping Jiang, Trevor D McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validationEric S Martin, Peter J Belmont, Mark J Sinnamon, et al.
Pageof 1